3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Pancreatic Neoplasms
2
Sarcoma
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Melanoma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
Bevacizumab
25
Fluorouracil
23
Leucovorin
22
Cetuximab
22
Oxaliplatin
19
pembrolizumab
14
Specimen Handling
11
Irinotecan
10
Nivolumab
8
Magnetic Resonance Spectroscopy
8
Biopsy
7
atezolizumab
6
fludarabine
5
encorafenib
5
Pemetrexed
5
Panitumumab
5
HMPL-013
5
Gemcitabine
5
Folfox protocol
5
Cisplatin
5
Carboplatin
5
trifluridine tipiracil drug combination
4
balstilimab
4
Standard of Care
4
Immunoglobulin G
4
Disulfides
4
Cyclophosphamide
4
regorafenib
3
fludarabine phosphate
3
dehydroftorafur
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Colorectal Neoplasms
×
Genetic Counseling
×
30 days
×
Clear all
NCT05225428
2026-05-22
VERDI
Dana-Farber Cancer Institute
Phase NA
Recruiting
1,020 enrolled